Spectrum Pharma in-licenses IP related to certain uses of poziotinib

|About: Spectrum Pharmaceutica... (SPPI)|By:, SA News Editor

Spectrum Pharmaceuticals (NASDAQ:SPPI) inks an agreement with The University of Texas MD Anderson Cancer Center securing a license to intellectual property related to exon 20 and any unidentified discoveries related to the use of poziotinib. Financial terms are not disclosed.

The company is currently evaluating poziotinib, a pan-HER inhibitor, in a Phase 2 clinical trial in EGFR exon 20-mutant non-small cell lung cancer patients.

Previously: Spectrum Pharma's poziotinib shows encouraging treatment effect in mid-stage lung cancer study (April 10)

Subscribe for full text news in your inbox